NO20082264L - Histamin-3 reseptorantagonister - Google Patents

Histamin-3 reseptorantagonister

Info

Publication number
NO20082264L
NO20082264L NO20082264A NO20082264A NO20082264L NO 20082264 L NO20082264 L NO 20082264L NO 20082264 A NO20082264 A NO 20082264A NO 20082264 A NO20082264 A NO 20082264A NO 20082264 L NO20082264 L NO 20082264L
Authority
NO
Norway
Prior art keywords
compound
formula
disorder
disorders
congestion
Prior art date
Application number
NO20082264A
Other languages
English (en)
Inventor
Travis T Wager
Ramalakshmi Yegna Chandrasekaran
Todd William Butler
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20082264L publication Critical patent/NO20082264L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en forbindelse med formel I, I som definert heri, eller et farmasøytisk akseptabelt salt derav; en farmasøytisk sammensetning som inneholder en forbindelse med formel I, en fremgangsmåte for fremstilling av en forbindelse med formel I, en fremgangsmåte for behandling av en forstyrrelse eller tilstand som kan behandles ved å antagonisere histamin-H3-reseptorer, fremgangsmåten innbefatter administrering til et pattedyr som trenger slik behandling av en forbindelse med formel I, som beskrevet ovenfor, og en fremgangsmåte for behandling av en forstyrrelse eller tilstand valgt fra gruppen som består av depresjon, humørforstyrrelser, schizofreni, angstforstyrrelse, Alzheimers sykdom, oppmerksomhetssvikt hyperaktivitetsforstyrrelse (ADHD), psykotiske forstyrrelser, kognitive forstyrrelser, søvnforstyrrelser, fedme, svimmelhet, epilepsi, bevegelsessykdom, respiratoriske sykdommer, allergi, allergiinduserte luftveisresponser, allergisk rhinitt, nasal kongestion, allergisk kongestion, kongestion, hypotensjon, kardiovaskulær sykdom, sykdommer i GI-trakten, hyper- og hypomotilitet og syresekresjon i gastrointestinaltrakten, fremgangsmåten innbefatter administrering til et pattedyr som trenger slik behandling en forbindelse med formel I som beskrevet ovenfor.
NO20082264A 2005-10-27 2008-05-16 Histamin-3 reseptorantagonister NO20082264L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73099605P 2005-10-27 2005-10-27
PCT/IB2006/002977 WO2007049123A1 (en) 2005-10-27 2006-10-16 Histamine-3 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20082264L true NO20082264L (no) 2008-07-22

Family

ID=37776539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082264A NO20082264L (no) 2005-10-27 2008-05-16 Histamin-3 reseptorantagonister

Country Status (39)

Country Link
US (2) US8158673B2 (no)
EP (1) EP1951660B1 (no)
JP (2) JP4319245B2 (no)
KR (1) KR101025358B1 (no)
CN (1) CN101296898B (no)
AP (1) AP2403A (no)
AR (1) AR056879A1 (no)
AU (1) AU2006307645B2 (no)
BR (1) BRPI0617797A2 (no)
CA (1) CA2621323C (no)
CR (1) CR9910A (no)
CU (1) CU23806B7 (no)
DK (1) DK1951660T3 (no)
DO (1) DOP2006000239A (no)
EA (1) EA013602B1 (no)
EC (1) ECSP088373A (no)
ES (1) ES2444370T3 (no)
GE (1) GEP20104937B (no)
GT (1) GT200600471A (no)
HN (1) HN2006036385A (no)
HR (1) HRP20140061T1 (no)
IL (1) IL189866A (no)
MA (1) MA29888B1 (no)
MY (1) MY145001A (no)
NI (1) NI200800132A (no)
NL (1) NL1032713C2 (no)
NO (1) NO20082264L (no)
NZ (1) NZ566488A (no)
PE (1) PE20070720A1 (no)
PL (1) PL1951660T3 (no)
PT (1) PT1951660E (no)
RS (2) RS20080173A (no)
SI (1) SI1951660T1 (no)
TN (1) TNSN08150A1 (no)
TW (1) TWI318206B (no)
UA (1) UA88719C2 (no)
UY (1) UY29882A1 (no)
WO (1) WO2007049123A1 (no)
ZA (1) ZA200803130B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
AU2008208653B2 (en) 2007-01-22 2012-11-22 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
CN101835750B (zh) 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
RU2451016C2 (ru) * 2007-12-07 2012-05-20 Пфайзер Инк. Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида
CA2721303C (en) * 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US20110201623A1 (en) 2010-02-18 2011-08-18 Uczynski Michael A Crystalline Form Of A Cyclopropyl Benzamide Derivative
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
CA2925743C (en) 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
PE20161364A1 (es) 2014-04-01 2016-12-25 Pfizer CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
CR20160455A (es) 2014-04-10 2016-12-16 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
ES2832893T3 (es) 2015-06-17 2021-06-11 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
PL3419979T3 (pl) 2016-02-23 2020-06-29 Pfizer Inc. Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
HUE054857T2 (hu) 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
WO2018163066A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2018163030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
CN110944998B (zh) 2017-06-22 2022-08-16 辉瑞大药厂 二氢-吡咯并-吡啶衍生物
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
WO2022182658A1 (en) 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Use of aprepitant for treating alzheimer's disease
CN116514645A (zh) * 2023-04-08 2023-08-01 绍兴上虞华伦化工有限公司 二氟-4溴苯甲醛及其制备工艺
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
JP2004131497A (ja) * 2002-09-18 2004-04-30 Satoshi Shuto シスシクロプロパン誘導体
CA2532236C (en) * 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
CN1960969B (zh) * 2004-04-01 2012-03-28 伊莱利利公司 组胺h3受体药物、其制备方法及治疗用途
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
DE602006018301D1 (de) 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
AU2008208653B2 (en) * 2007-01-22 2012-11-22 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
CA2621323C (en) 2010-08-24
JP2009161554A (ja) 2009-07-23
ES2444370T3 (es) 2014-02-24
EP1951660B1 (en) 2013-12-11
CU20080069A7 (es) 2009-12-17
BRPI0617797A2 (pt) 2011-08-09
UY29882A1 (es) 2007-05-31
CN101296898B (zh) 2013-07-24
NZ566488A (en) 2011-07-29
PL1951660T3 (pl) 2014-04-30
US8389743B2 (en) 2013-03-05
EA013602B1 (ru) 2010-06-30
IL189866A0 (en) 2008-11-03
DK1951660T3 (da) 2014-01-27
CU23806B7 (es) 2012-04-15
KR20080054413A (ko) 2008-06-17
RS53153B (sr) 2014-06-30
MA29888B1 (fr) 2008-10-03
AP2008004401A0 (en) 2008-04-30
JP2009513619A (ja) 2009-04-02
WO2007049123A1 (en) 2007-05-03
IL189866A (en) 2012-06-28
AR056879A1 (es) 2007-10-31
HN2006036385A (es) 2009-10-30
TW200800886A (en) 2008-01-01
TNSN08150A1 (fr) 2009-10-30
NI200800132A (es) 2010-02-15
CA2621323A1 (en) 2007-05-03
TWI318206B (en) 2009-12-11
AU2006307645A1 (en) 2007-05-03
ZA200803130B (en) 2009-01-28
SI1951660T1 (sl) 2014-02-28
UA88719C2 (ru) 2009-11-10
PE20070720A1 (es) 2007-08-11
AP2403A (en) 2012-05-04
KR101025358B1 (ko) 2011-03-28
HK1124831A1 (en) 2009-07-24
JP5064427B2 (ja) 2012-10-31
EP1951660A1 (en) 2008-08-06
EA200800946A1 (ru) 2008-10-30
GEP20104937B (en) 2010-03-25
HRP20140061T1 (hr) 2014-02-14
ECSP088373A (es) 2008-05-30
NL1032713C2 (nl) 2007-10-09
US20080096955A1 (en) 2008-04-24
CR9910A (es) 2008-05-16
JP4319245B2 (ja) 2009-08-26
DOP2006000239A (es) 2007-04-30
NL1032713A1 (nl) 2007-05-01
CN101296898A (zh) 2008-10-29
MY145001A (en) 2011-12-15
AU2006307645B2 (en) 2012-02-16
PT1951660E (pt) 2014-02-10
RS20080173A (sr) 2009-07-15
US8158673B2 (en) 2012-04-17
US20120220568A1 (en) 2012-08-30
GT200600471A (es) 2007-06-08

Similar Documents

Publication Publication Date Title
UA88719C2 (ru) Антагонисты рецепторов гистамина-3
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
WO2007105053A3 (en) Tetralines antagonists of the h-3 receptor
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
DE602006018301D1 (de) Histamin-3-rezeptorantagonisten
WO2007138431A3 (en) Azabicyclic ether histamine-3 antagonists
MX2009007782A (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma.
BRPI0513486A (pt) derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3
JP2009161554A5 (no)
BRPI0507374A (pt) moduladores do receptor de histamina-3
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
JP2022105159A (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
BRPI0513444A (pt) antagonistas do receptor da histamina 3
CN108883110A (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
NO20072193L (no) 5-sulfonyl-1-piperidinylsubstituerte indolderivater som 5-HT6 reseptorantagonister for behandling av CNS lidelser
BRPI0510501A (pt) antagonistas do receptor 3 de histamina
EA201170352A1 (ru) Способы лечения расстройств цнс
JP2024514366A (ja) 可溶性エポキシドヒドロラーゼ阻害剤としてのピペリジン尿素誘導体
BRPI0516079A (pt) antagonistas de receptor de histamina-3
EP3400940A1 (en) Prophylactic or therapeutic agent for delirium
WO2006024955A8 (en) Azabicyclic amine histamine-3 receptor antagonists
BRPI0512567A (pt) compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
BRPI0816571A2 (pt) "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6"
MX2010006162A (es) Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application